AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06656507 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadro Iliac Plane Block (QIPB)
Description: The Quadro Iliac Plane Block (QIPB) will be performed pre-awakening in patients undergoing lumbar vertebra surgeries. Using a low-frequency convex ultrasound transducer (2-6 MHz), the spinal process will be identified at the L3 level in a prone-positioned patient. The transducer will be moved laterally to locate the transverse process within the erector spinae muscle and then rotated to the parasagittal plane to identify the Quadratus Lumborum Muscle (QLM) attachment to the iliac crest. A 22G x 100 mm block needle will be advanced under ultrasound guidance, and 50 mg (0.25%) bupivacaine will be injected bilaterally into the fascia beneath the QLM. This technique is designed to provide effective postoperative pain control by blocking the nerves in the quadratus lumborum plane.
Study NCT06656507 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block (ESP)
Description: The Erector Spinae Plane Block (ESP) will also be performed pre-awakening. A linear ultrasound probe will be placed transversely at the level of the L3 vertebra to visualize the transverse process. A block needle will be advanced under ultrasound guidance until it touches the transverse process, after which the needle will be withdrawn 1 mm. Fifty milligrams (0.25%) bupivacaine will then be administered bilaterally. The ESP block aims to provide postoperative analgesia by blocking sensory nerves in the erector spinae plane.
Study NCT06150300 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary rehab program
Description: Exercise videos, breathing exercises, and educational messages delivered virtually
Study NCT06150300 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Breathing exercises and educational messages
Study NCT04252677 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Obesity Prevention
Description: This intervention includes content specific to obesity behaviors-related health information, motivation, and behavioral skills.
Study NCT04252677 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Obesity Prevention
Description: This intervention includes content specific to obesity behaviors-related health information, motivation, and behavioral skills.
Study NCT04252677 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Literacy
Description: This intervention includes content specific to improving health literacy.
Study NCT05497453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX-2002
Description: OTX-2002 is a lipid nanoparticle (LNP) that contains a biscistronic mRNA that codes for 2 independent epigenomic controllers.
Study NCT05497453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitor One
Description: Tyrosine Kinase Inhibitor
Study NCT05497453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitor Two
Description: tyrosine kinase inhibitor
Study NCT05497453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Checkpoint Inhibitor, Immune
Description: monoclonal antibody that binds to PD-1 or PD-L1
Study NCT05926648 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVSENSOR00061
Description: Noninvasive pulse oximetry and pulse rate device
Study NCT06386380 — intervention group
Intervention type: OTHER
Intervention: Rheumatic diseases Mistreatment Scale (RDMS)
Description: In 2012, Giraldo-Rodríguez developed and validated the Geriatric Mistreatment Scale (GAS); translation, cultural adaptation, and validation were performed prior to its application.
Study NCT06386380 — intervention group
Intervention type: OTHER
Intervention: Routine assessment of patient index data 3 (RAPID-3)
Description: RAPID- 3 measures: function, pain, and patient global status estimate. Each of the three individual measures is scored 0 to 10, for a total of 30
Study NCT06386380 — intervention group
Intervention type: OTHER
Intervention: Health Assessment Questionnaire (HAQ)
Description: The HAQ is based on five patient-centered dimensions: disability, pain, medication effects, costs of care, and mortality.
Study NCT06386380 — intervention group
Intervention type: OTHER
Intervention: WHOQOL-BREF
Description: WHOQOL-BREF is a 26-item instrument consisting of four domains: physical health, psychological health, social relationships, and environmental health; it also contains QOL and general health items
Study NCT06386380 — intervention group
Intervention type: OTHER
Intervention: Depression, Anxiety and Stress Scale (DASS-21)
Description: DASS-21 is a set of three self-report scales designed to measure the emotional states of depression, anxiety, and stress. Each of the three DASS-21 scales contains seven items, divided into subscales with similar content.
Study NCT06386380 — intervention group
Intervention type: OTHER
Intervention: Brief Resilient Coping Scale
Description: The Brief Resilient Coping Scale is a 4-item measure designed to capture tendencies to cope with stress in a highly adaptive manner.
Study NCT06386380 — intervention group
Intervention type: GENETIC
Intervention: Expression of CDKN2A /p16INK4a
Description: CDKN2A/p16INK4a expression will be measured using the Taqman qPCR assay (TaqMan Universal Master Mix II, with UNG, Applied Biosystems, Foster City, USA) according to the manufacturer's specifications.
Study NCT06386380 — intervention group
Intervention type: OTHER
Intervention: Immunophenotype of leukocyte subpopulations
Description: CD4+ and CD8+ subpopulations will be analyzed. Blood samples will be analyzed by 8-color flow cytometry (Becton Dickinson Canto II cytometer) using fluorescently labeled antibodies from Biolegend Inc. (San Diego, USA).
Study NCT06386380 — intervention group
Intervention type: GENETIC
Intervention: Telomere length
Description: The rLTL will be estimated by quantitative monochromatic multiplex PCR (MM-qPCR). Integrated DNA Technologies, Inc. (IDT, Coralville, IA, USA) will synthesize the primers used for telomere measurements.
Study NCT06386380 — intervention group
Intervention type: OTHER
Intervention: Cellular senescence
Description: Expression of co-stimulatory molecules and surface receptors CD27- and CD28-
Study NCT05728333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirofiban
Description: Intravenous tirofiban before endovascular thrombectomy.
Study NCT05728333 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alteplase
Description: Intravenous alteplase before endovascular thrombectomy.
Study NCT04976439 — intervention group
Intervention type: OTHER
Intervention: co-occuring mutation
Description: APC, TP53, PIK3CA, KRAS APC, TP53, PIK3CA, MLH1 APC, TP53, PIK3CA, KRAS, and MLH1 APC, TP53, PIK3CA
Study NCT05660382 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Miconazole (2%) oil and mineral oil
Description: Twice daily application, for 14 days.
Study NCT05660382 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice daily application, for 14 days
Study NCT04710004 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Asynchronous distributed multi-electrode stimulation (ADMES) using an implantable neurostimulation device
Description: Participants will receive asynchronous pulses distributed across a multi-electrode array of 16 micro-electrodes and stimulating at low (theta) frequencies.
Study NCT04818073 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New FINGER
Description: New FINGER exoskeleton is a robotic device that can provide assistance and resistance to thumb and finger movement
Study NCT05816382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-861
Description: TAK-861 tablets
Study NCT05490355 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency Ablation (RFA)
Description: RFA involves heating of periarticular nerves using continuous RFA (80-90C for 60-90 seconds) that results in electromodulation and denervation reducing pain. It can be done under fluoroscopy or CT guidance. CT guidance has additional benefit of better localization of the nerves, as opposed to simple bony landmarks used in fluoroscopy, since nerve branching variations are common and will be used in this study.
Study NCT05490355 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Perineural Steroid Injection
Description: Perineural Steroid Injections involve CT guided injection of Local Anesthetic and Steroid into a nerve root of the spine to provide ongoing pain relief.
Study NCT05490355 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perineural Steroid Injection
Description: Perineural Steroid Injections involve CT guided injection of Local Anesthetic and Steroid into a nerve root of the spine to provide ongoing pain relief.
Study NCT05607316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Consistent with previous studies and clinical recommendations, subjects will initiate treatment at metformin 500 mg twice daily and increase to 1000 mg twice daily only after they have tolerated the treatment (details below).~Study Visit 1 (Week 1) - Study Visit 2 (Week 2) Subjects will be directed to take metformin 500 mg twice daily.~Study Visit 2 (Week 2) - Study Visit 5 (Week 24) If initial metformin dose is tolerated, subjects will be directed to increase the dose to 1000 mg by mouth twice daily for the remainder of the study.
Study NCT05359614 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoolSculpting Elite combined with CoolTone Treatments
Description: Coolsculpting treatment combined with Cooltone treatments for the banana roll region of the buttocks.
Study NCT05359614 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CoolSculpting Elite
Description: Coolsculpting treatment alone for the banana roll region of the buttocks
Study NCT05793281 — intervention group
Intervention type: OTHER
Intervention: No Drug
Description: Retrospective data analysis, the dataset for this study will be extracted from the C-CAT database.
Study NCT06657833 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Percutaneous coronary intervention of a calcified nodule with intravascular lithotripsy followed by drug eluting balloon
Description: Percutaneous coronary intervention of a calcified nodule with intravascular lithotripsy followed by drug eluting balloon
Study NCT06657833 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Percutaneous coronary intervention of a calcified nodule with intravascular lithotripsy followed by drug eluting stent
Description: Percutaneous coronary intervention of a calcified nodule with intravascular lithotripsy followed by drug eluting stent
Study NCT06424392 — intervention group
Intervention type: OTHER
Intervention: General Health Questionnaire (GHQ-12)
Description: Anxiety and depression self-reported scales for both parents
Study NCT06424392 — intervention group
Intervention type: OTHER
Intervention: State-Trait Anxiety Inventory (STAI-Y)
Description: Anxiety and depression self-reported scales for both parents
Study NCT06424392 — intervention group
Intervention type: OTHER
Intervention: Revised Children's Manifest Anxiety Scale (RCMAS)
Description: Anxiety and depression self-reported scales for children
Study NCT06424392 — intervention group
Intervention type: OTHER
Intervention: World Health Organization Quality of Life (WHOQOL-BREF)
Description: Quality of life self-reported scales for parents
Study NCT06424392 — intervention group
Intervention type: OTHER
Intervention: Parental Educational Competence Self-Evaluation Questionnaire Questionnaire d'Auto-Évaluation de la Compétence Éducative Parentale (QAECEP)
Description: Parental Educational Competence Self-Evaluation self-reported Questionnaire for parents
Study NCT06424392 — intervention group
Intervention type: OTHER
Intervention: Parental interview
Description: The interview will only last about ten minutes and will take place during the first call, if the parents have agreed and are sufficiently available to answer. If the parents are not available, an appointment can be made at a later date
Study NCT06664827 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delfi PTS Blood Flow Restriction Tourniquet System
Description: In Houston Methodist rehabilitation clinics these devices are used as standard of care for BFR therapy in many post-operative treatments. General guidelines suggest using ranges between 30% - 80% of limb occlusion pressure (LOP). In our previous research efforts involving BFR the investigators have adhered to these guidelines and experienced no adverse events while observing these ranges to be well tolerated by subjects.
Study NCT05281471 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: olvimulogene nanivacirepvec
Description: Olvi-Vec is an engineered oncolytic vaccinia virus
Study NCT05281471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum chemotherapy: carboplatin (preferred) or cisplatin
Description: Administered according to local practice
Study NCT05281471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platinum chemotherapy: carboplatin (preferred) or cisplatin
Description: Administered according to local practice
Study NCT05281471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin
Description: Administered according to local practice
Study NCT05281471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin
Description: Administered according to local practice
Study NCT05281471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab (or biosimilar)
Description: Administered according to local practice
Study NCT05281471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab (or biosimilar)
Description: Administered according to local practice
Study NCT06607523 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Inulin
Description: Inulin, 4g twice daily for 42 days
Study NCT06608693 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF stretching
Description: Subjects lay supine on a treatment table, holding one knee to the chest and letting the other leg extend freely toward the floor at the end of the table. This protocol was adapted from previous studies. The hip joint was carefully and gradually lowered towards the floor, with the knee flexing at a 90-degree angle until the individual experienced a mild stretching sensation (Visual analog scale:4-6). Then, the subject performed a sub-maximal voluntary isometric contraction by utilizing the flexor muscles for 20 seconds while resisting the applied force exerted by an examiner through the utilization of a hand-held dynamometer (K-Force Muscle Control). The examiner proceeded to passively manipulate the leg to achieve the desired range of motion (ROM), maintaining it for 20 seconds. This process was repeated six times for each limb. The patient rested for 2 minutes before applying the same technique to the other side.
Study NCT06608693 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static stretching group
Description: While the patient was lying supine, the hip and knee joints on the non-stretch side were kept in 90⸰ flexion. A sandbag was positioned on the side to be stretched, specifically proximal to the patella, in order to induce a moderate sensation of stretching in the patient. Subsequently, a force was exerted in the direction of hip extension for a duration of 30 seconds. Afterward, the patient was instructed to relax. This process was repeated a total of six times, with a designated 20-second rest period between each repetition. The patient took a two-minute rest before the same technique was applied to the other side. There was no specific order on which side to apply the technique.
Study NCT06608186 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetrorelix drug
Description: a drug injection daily sc. from day 5 of stimulation till hCG trigger day
Study NCT06608186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drospirenone drug
Description: A drug drospirenone in the form of 1 tablet / d from day 5 of stimulation till hCG trigger day
Study NCT06607549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loncastuximab tesirine and rituximab (Lonca-R)
Description: Patients will receive stereotactic radiosurgery (SRS) followed by a brain MRI approx. 4 weeks after SRS. This will be followed by loncastuximab tesirine and rituximab administered intravenously for a total of 6 cycles (every 21 days).
Study NCT06498960 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CereVasc eShunt System
Description: The eShunt System consists of the following components:~* eShunt Implant~* eShunt Delivery Catheter and Transfer Tool~* eShunt Anchor
Study NCT06498960 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VP Shunt
Description: Control arm - VP shunt
Study NCT05182411 — intervention group
Intervention type: OTHER
Intervention: assessment
Description: Turkish version of Leg Activity Measure Rivearmead Mobility Index Nottingham Health Profile Functional Independence Measures
Study NCT05664308 — intervention group
Intervention type: OTHER
Intervention: Clinical follow-up (ECG)
Description: Clinical follow-up with a consultation at the University Hospital at 3, 6, and 12 months, with an ECG at each visit.
Study NCT05664308 — intervention group
Intervention type: OTHER
Intervention: Ongoing monitoring
Description: Once operated, patients will be monitored remotely via a computerized data transfer routine anonymized by the WITHINGS software, based on the data from the watch.~It's contractually agreed with WITHINGS that the transmissions will be scheduled and transmitted weekly to the center.
Study NCT05177146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Ketamine (IV)
Description: A sterile form of ketamine hydrochloride will be administered over 40-min IV infusion twice per week on non-consecutive days for four weeks. Dosing schedule is determined based on patient's weight, clinical response and tolerability. First treatment session dose will be calculated based on 0.5 mg/kg. Further dose increase will be determined by the study physician. Dose increase will not exceed 0.8 mg/kg. Patients will be closely monitored by available trained personnel with MD being present on site for the full duration of the 2-h supervision period. Specifically, IV induction will be performed under the direct supervision of anesthesiologist or delegate and psychiatrist. Vital signs will be monitored every 30 minutes during the supervision period. Side effects will be managed by the medical team administering the treatment. If required, appropriate rescue medications will be provided depending on the nature of the adverse event.
Study NCT06373341 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR training for arm and hand rehabilitation
Description: The intervention group will participate in training with a VR-exergame for 4 weeks after inclusion. For this training a Meta Quest VR-headset with a game specifically designed for and with ICU patients that was previously pilot tested for feasibility and safety will be used under supervision of a researcher or caregiver until the patient feels ready to practice alone.
Study NCT06587529 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Set Me Free Project's (SMFP) READY to Stand (RTS)© Curriculum
Description: Students will receive the Ready to Stand (RTS)© programming over six school days, spread over six weeks. The program is delivered in mixed-gender groups of 20 to 40 students and includes videos, small and large group discussions, activities, worksheets, and ample opportunities for skill-building. This curriculum is intended to be one piece of comprehensive prevention strategies that has the potential to make immediate and sustained impacts on reducing rates of CSEC perpetration in the lives of youth, including those most vulnerable to this pernicious crime.
Study NCT05254899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 monoclonal antibody
Description: 200mg iv on Day 1 of each 14-day cycle for 3 cycles in induction treatment; 200mg iv on Day 1,15, 29 during RT treatment
Study NCT05254899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: 3000 U/m2 im on Day 2 of each 14-day cycle for 3 cycles in induction treatment
Study NCT05254899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1g/m2 iv on Day 2 of each 14-day cycle for 3 cycles in induction treatment
Study NCT05254899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 1g/m2 iv on Day 2 of each 14-day cycle for 3 cycles in induction treatment
Study NCT05254899 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Involved site radiotherapy
Description: Involved site radiotherapy according to the ILROG guideline with primary tumor dose of 50-56Gy 14-28 days after inductive therapy
Study NCT04912492 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: RealConsent1.0
Description: A web-based multi-media sexual violence prevention program that enhances knowledge and skills for effective consent for sex and for prosocial bystander behaviors.
Study NCT04912492 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RealConsent2.0
Description: A revised and updated web-based multi-media sexual violence prevention program that enhances knowledge and skills for effective consent for sex and for prosocial bystander behaviors, but also integrates new program segments into RealConsent 1.0 specific to how alcohol use can inhibit SV intervention at multiple steps of the decision-making process.
Study NCT04912492 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Management
Description: A web-based multimedia program designed to help individuals recognize the symptoms and sources of stress and provide them with a wide variety of powerful tools for managing stress.
Study NCT04912492 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol intoxication
Description: Men assigned to moderate alcohol dose condition (target BrAC .08%) with NIAAA approved alcohol administration procedures